This segment features Dr. Steve Crawford discussing vaccine policies in pediatric practices, including claims that insurance reimbursement structures and federal quality measures can influence physician behavior and patient dismissal decisions. The conversation expands into broader claims about pharmaceutical incentives, disclosure requirements, and financial relationships between drug companies and physicians. Dr. Crawford also revisits his COVID-era treatment approaches, including early use of hydroxychloroquine and ivermectin, critiques of vaccine policy during the pandemic, and his view that adverse event signals were not adequately addressed. The discussion closes with commentary on media coverage and whether dissenting medical opinions were adequately reported or investigated.
Hashtags:
#Vaccines #COVID19 #Ivermectin #Hydroxychloroquine #MedicalPolicy #HealthcareDebate #PharmaceuticalIndustry #SecondOpinion #PublicHealth #InsuranceReimbursement

Apr 21, 2026



